Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
AQP4-IgG Seropositive NMOSD and Systemic Lupus Erythematosus Shown to Overlap
September 12th 2023A recent systematic review showed that AQP4+NMOSD in patients with systemic lupus erythematosus can mimic neuropsychiatric manifestations, frequently occur after the onset of lupus or may predate, and necessitate indefinite treatment.
Treatment Effect of Neflamapimod Enriched When Excluding High P-Tau181 Level Patients
September 11th 2023The combined preclinical and clinical data with neflamapimod suggest the therapy has potential to be the first disease-modifying treatment for dementia with Lewy Bodies, demonstrating a positive impact on cognition, function, and mobility.
Efforts Made to Improve the Rett Syndrome Behavior Questionnaire
September 11th 2023The Rett Syndrome Behavior Questionnaire’s implementation as global outcome measure in FDA-approved trials was the result of its comprehensive nature since it includes behavior-related symptom questions as well as questions for regular behaviors.
SomnoRing Appears Usable and Acceptable to Assess Sleep Health in Diverse Populations
September 10th 2023Recent research highlights how advanced technology like remote monitoring devices or wearables and smartphone-based apps for sleep health can be delivered at the point of care to meet the needs of patients.
Antinuclear Antibodies Associated With Higher Disability and Disease Severity in NMOSD
September 8th 2023Antinuclear antibodies seem to be more associated with severe disease activity and poor prognosis among patients with NMOSD, which further implies that they may be potentially used as a prognostic marker for the disease.
Autonomic Dysfunction Significantly Associated With Decreased Quality of Life in NMOSD and MS
September 7th 2023Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis compared with those with NMOSD, although the difference was not statistically significant.
Neurobiological Insights Into Gait and Balance Control in Parkinson Disease
September 5th 2023Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.
Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity
September 4th 2023On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.
ALS Agent CNM-Au8 Displays Survival Benefit and Delay of Clinical Worsening in 2 Year Follow-Up
September 2nd 2023Findings from an open-label extension trial among 45 patients with ALS showed a significant median survival benefit of 19.3 months and a significant 52% decreased risk of ALS clinical worsening events after treatment.
Machine Learning Algorithm Accurately Diagnoses Parkinsonian Syndromes, Study Shows
September 1st 2023Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.
Duchenne Agent Pamrevlumab Fails to Meet Primary End Point in Phase 3 LELANTOS-2 Trial
August 31st 2023Despite pamrevlumab being generally safe and well tolerated, the potential first-in-class connective tissue growth factor inhibitor antibody did not meet its primary endpoint in a phase 3 trial for ambulator Duchenne muscular dystrophy.
Revolutionizing Dementia Research With Synuclein Biomarker Tests
August 31st 2023Russell Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the ongoing collaboration focused on exploring the role of misfolded synuclein traditionally associated with Parkinson disease and in various forms of dementia.
Nusinersen Exhibits Long-Term Safety and Efficacy Across Wide Spectrum of SMA Severity
August 31st 2023Findings from a real-world study among 120 patients with SMA suggests that nusinersen administration is safe and well tolerated, with only 30% of the patients mostly experiencing mild adverse events.
Machine Learning Algorithm Shows Ability to Distinguish Tic From NonTic Movements
August 31st 2023Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.
Insights on the Innovative FDA-Cleared Retitrack Device for Ocular Motor Function
August 29th 2023Christy Sheehy, PhD, chief executive officer and cofounder of C. Light Technologies, talked about the FDA clearance of Retitrack—retinal eye-movement monitor—and how the device holds promise for facilitating more accurate ocular motor assessments at bedside.
Machine Learning Approach Shows Strong Ability to Predict Gait Dysfunction in Parkinson Disease
August 29th 2023Previous neuroimaging studies in Parkinson disease suggest an altered interaction at a structural and functional level between cortical and subcortical areas of the brain that each contribute to gait dysfunction.
NeurologyLive® Clinician of the Month Spotlight: Gary Hisch, MD
August 28th 2023As part of our monthly clinician spotlight, NeurologyLive® highlighted expert Gary Hisch, MD, pediatric neurologist at Cleveland Clinic, who oversees programs for neuromuscular disorders such as for patients with spinal muscular atrophy.
Focused Ultrasound Treatment for Essential Tremor Maintains Efficacy After 5 Years
August 23rd 2023Five-year data revealed sustained and significant improvement for patients with tremor as well as an overall improvement in quality of life measures and without any progressive or delayed complications.
Genome Sequencing Shows Strong Efficacy in Diagnosing Infant Genetic Disorders
August 22nd 2023In a clinical study diagnosing genetic disorders, genomic sequencing did not report 19 variants found by a targeted neonatal gene-sequencing test and the targeted panel did not report 164 variants recognized by genomic sequencing.
Exon 44 Skipping Agent AOC 1044 Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy
August 16th 2023AOC 1044, an exon 44-targeting agent, holds potential to fill a major unmet need for patients with Duchenne muscular dystrophy, as there are currently there are no approved therapies approved targeting this mutation.
New Assay Demonstrates Ability to Detect Abnormal α-Synuclein in Neurodegenerative Diseases
August 16th 2023A new platform showed the ability to effectively detect patients with synucleinopathies using serum samples, improving the time and accuracy for diagnosis of specific neurodegenerative diseases such as Parkinson disease.